

Table S3. Bacterial strains used in this study.

Strain	AB ^R ¹⁾	Origin	Application
<i>E. coli</i> BL21 Gold (DE3)	Tet ^R	Stratagene	Cloning, expression
ClearColi® BL21 (DE3)	-	Lucigen	Endotoxin-free expression
<i>E. coli</i> Sure	Tet ^R , Kan ^R , Cam ^r	Stratagene	Protein expression
<i>E. coli</i> XL1Blue MRF'	Tet ^R	Stratagene	Protein expression
<i>S. aureus</i> SA113	MSSA	(Reference 1) ²⁾	Activity assays
<i>S. aureus</i> Newman	MSSA	(Reference 2) ³⁾	Activity assays
<i>S. aureus</i> Cowan	MSSA	(Reference 3) ⁴⁾	Activity assays
<i>S. aureus</i> USA300 JE-2	MRSA	(Reference 4) ⁵⁾	Activity assays
<i>S. aureus</i> ZH123	MRSA	Clinical isolate ⁶⁾	Activity assays
<i>S. aureus</i> ZH313	MRSA	Clinical isolate ⁶⁾	Activity assays
<i>S. aureus</i> ZH133	MRSA	Clinical isolate ⁶⁾	Activity assays

¹⁾ Antibiotic resistances: - no resistances, Tet^R: tetracycline resistant, Kan^R: kanamycin resistant, Cam^r: chloramphenicol resistant, MSSA: methicillin susceptible *S. aureus*, MRSA: methicillin resistant *S. aureus*

²⁾ Andreas Peschel, University of Tübingen, Germany

³⁾ ATCC 25904

⁴⁾ ATCC 12598

⁵⁾ NR-46543, Network on Antimicrobial Resistance in *Staphylococcus aureus* (NARSA)

⁶⁾ Brigitte Berger-Bächi, Institute of Medical Microbiology, University of Zurich, Switzerland

References

1. Iordanescu S, Surdeanu M. 1976. Two restriction and modification systems in *Staphylococcus aureus* NCTC8325. J Gen Microbiol 96:277-81.
2. Duthie ES, Lorenz LL. 1952. Staphylococcal coagulase; mode of action and antigenicity. J Gen Microbiol 6:95-107.
3. Bohacek J, Kocur M, Martinec T. 1971. Deoxyribonucleic acid base composition of serotype strains of *Staphylococcus aureus*. J Gen Microbiol 68:109-13.
4. Fey PD, Endres JL, Yajjala VK, Widholm TJ, Boissy RJ, Bose JL, Bayles KW. 2013. A genetic resource for rapid and comprehensive phenotype screening of nonessential *Staphylococcus aureus* genes. mBio 4:e00537-12.